Showing 9021-9030 of 21418 results for "".
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
https://reachmd.com/programs/cme/the-next-generation-of-care-new-treatment-frontiers-in-immunotherapy-resistant-advanced-squamous-nsclc/56403/Navigate immunotherapy-resistant advanced squamous NSCLC with strategies to identify resistance mechanisms and individualize treatment sequencing.Frontline Insights: Emerging Therapeutic Strategies in HNSCC
https://reachmd.com/programs/cme/Frontline-Insights-Emerging-Therapeutic-Strategies-in-HNSCC/49223/Review emerging therapeutic strategies in HNSCC across disease states and learn to compare safety profile to improve AE recognition, prevention, and management.Practical Dermatology Roundtable: The Role of Adjuvant Skin Cleansing and Moisturizing in Treating Psoriasis and Other Inflammatory Diseases, Ch. 5
https://reachmd.com/programs/the-practical-dermatology-roundtable/practical-dermatology-roundtable-the-role-of-adjuvant-skin-cleansing-and-moisturizing-in-treating-psoriasis-and-other-inflammatory-diseases-ch-5/56873/In the fifth installment of this eight-part series, host Ted Lain, MD, MBA, FAAD, and guests Zoe Diana Draelos, MD, and Firas George Hougeir, MD, FAAD, explore how these findings may generalize to other inflammatory skin conditions and reviews the unique properties of the skincare products used in tMenin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
https://reachmd.com/programs/cme/menin-inhibitors-in-aml-six-clinical-showdowns-that-shape-real-world-practice/57259/Expert faculty explore six real-world clinical decision points in menin inhibitor use for NPM1-mutated AML.Beyond IOP: Integrating Ocular Surface Resilience Into Glaucoma Management
https://reachmd.com/programs/cme/beyond-iop-integrating-ocular-surface-resilience-into-glaucoma-management/49097/Our experts discuss management strategies for individualized ocular surface rehabilitation while maintaining optimal IOP control in patients with glaucoma.ASCVD Playbook | Closing the Gaps, One Inning at a Time
https://reachmd.com/programs/cme/ascvd-playbook-closing-the-gaps-one-inning-at-a-time/54284/Step up to the plate with evidence-based strategies to identify patients with high-risk ASCVD, optimize LDL-C, and up your game in secondary prevention.Evaluating Alemtuzumab in Adult ALL: Insights from a Phase 1/2 Clinical Trial
https://reachmd.com/programs/project-oncology/evaluating-alemtuzumab-in-adult-all-insights-from-a-phase-12-clinical-trial/32993/Alemtuzumab may have potential as an adult acute lymphoblastic leukemia treatment. Dive deeper into its safety, efficacy, and implications for care.Molecular Precision: How Myosin Inhibitors Redefine Control
https://reachmd.com/programs/cme/molecular-precision-how-myosin-inhibitors-redefine-control/54839/Explore how cardiac myosin inhibitors are reshaping obstructive HCM management, from unmet needs to individualized, evidence-based treatment.No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
https://reachmd.com/programs/acc-action-center/no-improvements-in-cv-outcomes-at-90-days-with-human-apoa-1-infusions-post-mi/24288/ACC.24 - Michael Gibson shares the results of the AEGIS-II trial, in which infusions of human ApoA-1 - the building block of HDL-c - with CSL112 in the first month after an MI did not improve CV mortality, MI or stroke at 90 days.Closing the Gaps: Global Implementation of Lipid Guidelines
https://reachmd.com/programs/cme/gaps-global-implementation-lipid-guidelines/54672/A new modular CME-accredited program designed to support clinicians in translating evolving lipid guidelines into everyday practice. Delivered as a 60-minute webcast, divided into chapters for convenience, it integrates U.S. and international perspectives and focuses on equitable cardiovascular care